Who is sponsoring NCT00193375?

NCT00193375 is sponsored by SCRI Development Innovations, LLC.

What condition does NCT00193375 study?

NCT00193375 studies Lung Cancer.

What drugs are being tested in NCT00193375?

Interventions: Irinotecan, Carboplatin, Bevacizumab, Radiation.

What is the status of NCT00193375?

NCT00193375 is currently COMPLETED.

Last reviewed 2016-06-29 · How we verify

Phase II Trial of Concurrent Irinotecan, Carboplatin and Radiation Therapy Followed by Bevacizumab (Avastin) in the Treatment of Patients With Limited Stage Small Cell Lung Cancer

NCT00193375 Phase 2 COMPLETED Results posted

In this multicenter trial, we plan to evaluate the feasibility and toxicity of initial treatment with irinotecan/carboplatin/radiation therapy, followed by treatment with bevacizumab, in patients with limited stage small cell lung cancer.

Details

Lead sponsor	SCRI Development Innovations, LLC
Phase	Phase 2
Status	COMPLETED
Enrolment	60
Start date	2003-08
Completion	2008-05

Conditions

Lung Cancer

Interventions

Irinotecan
Carboplatin
Bevacizumab
Radiation

Primary outcomes

Number of Grade 3/4 Toxicities Patients Experienced on Maintenance Bevacizumab Following Chemoradiation for Limited Stage - Small Cell Lung Cancer (LS-SCLC) — 18 months
Toxicity was evaluated in all patients who received at least 1 dose of therapy, and graded according to CTCAE v. 3.